Formulation and Manufacture of Pharmaceuticals by Impregnation onto Porous Carriers

Fernando Muzzio (Inventor), Benjamin Glasser (Inventor), Plamen Grigorov (Inventor)

Research output: Innovation

Abstract

Figure 1. SEM Pictures of pure Neusilin ® and impregnated with Fenofibrate at 30% loading.


Invention Summary:

Rutgers scientists have developed a novel platform of pharmaceutical product development by utilizing fluid bed impregnation (FBI) of API solutions onto porous carriers. Impregnation of solutions into porous carriers allows extremely uniform distribution of small amounts of material, which can be used for drug dosage regulation. Currently, the method can be adjusted for drug content as low as 0.1% and as high as 10%, thus spanning the entire range of interest for poorly soluble, highly potent compounds in oral delivery applications. The drug release profile can also be controlled through the manufacturing process.

Since the impregnated material can be filled directly into capsules, many inactive substances that were previously required for formula stability throughout encapsulation (i.e. compression aids, glidants, surfactants, disintegrants, or lubricants) can be eliminated as well. Also, the FBI method is uniquely suited for drug formulation development and clinical supply manufacturing, as it is safer than processes that require drugs to be handled in dry, powder form.

Market Application:

  • Therapeutics
  • Clinical Supply Manufacturing
  • Product Formulation and Development
  • Drug Loading
  • Drug Delivery
  • Controlled Release
  • Porous Carrier Technology

Advantages:

  • Approach eliminates all API operations after synthesis and purification (i.e., crystallization, drying, milling) making issues related to API crystallinity, physical stability, flow, cohesion, electrostatics, and particle size distribution no longer relevant
  • Extremely uniform material content in finished dosages
  • Enhances deliverability of poorly soluble drugs
  • Significant simplification of product manufacturing sequence
  • Safety and environmental improvements
  • Simplified scale-up procedure
  • Reduced number of critical raw material attributes and control parameters

Intellectual Property & Development Status:

US patent application allowed, European patent application pending, available for licensing and/or research collaboration.

Original languageEnglish (US)
StatePublished - Aug 2018

Fingerprint

Drug Compounding
Pharmaceutical Preparations
Intellectual Property
Fenofibrate
Lubricants
Drug and Narcotic Control
Licensure
Crystallization
Static Electricity
Particle Size
Surface-Active Agents
Powders
Capsules
Technology
Safety
Research

Keywords

  • Drug Delivery
  • Drug Delivery Methods.
  • therapeutic

Cite this

@misc{6203dc60b0d840b19519e24ba86fb9cc,
title = "Formulation and Manufacture of Pharmaceuticals by Impregnation onto Porous Carriers",
abstract = "Figure 1. SEM Pictures of pure Neusilin {\circledR} and impregnated with Fenofibrate at 30{\%} loading. Invention Summary: Rutgers scientists have developed a novel platform of pharmaceutical product development by utilizing fluid bed impregnation (FBI) of API solutions onto porous carriers. Impregnation of solutions into porous carriers allows extremely uniform distribution of small amounts of material, which can be used for drug dosage regulation. Currently, the method can be adjusted for drug content as low as 0.1{\%} and as high as 10{\%}, thus spanning the entire range of interest for poorly soluble, highly potent compounds in oral delivery applications. The drug release profile can also be controlled through the manufacturing process. Since the impregnated material can be filled directly into capsules, many inactive substances that were previously required for formula stability throughout encapsulation (i.e. compression aids, glidants, surfactants, disintegrants, or lubricants) can be eliminated as well. Also, the FBI method is uniquely suited for drug formulation development and clinical supply manufacturing, as it is safer than processes that require drugs to be handled in dry, powder form. Market Application: Therapeutics Clinical Supply Manufacturing Product Formulation and Development Drug Loading Drug Delivery Controlled Release Porous Carrier Technology Advantages: Approach eliminates all API operations after synthesis and purification (i.e., crystallization, drying, milling) making issues related to API crystallinity, physical stability, flow, cohesion, electrostatics, and particle size distribution no longer relevant Extremely uniform material content in finished dosages Enhances deliverability of poorly soluble drugs Significant simplification of product manufacturing sequence Safety and environmental improvements Simplified scale-up procedure Reduced number of critical raw material attributes and control parameters Intellectual Property & Development Status: US patent application allowed, European patent application pending, available for licensing and/or research collaboration.",
keywords = "Drug Delivery, Drug Delivery Methods., therapeutic",
author = "Fernando Muzzio and Benjamin Glasser and Plamen Grigorov",
year = "2018",
month = "8",
language = "English (US)",
type = "Patent",

}

TY - PAT

T1 - Formulation and Manufacture of Pharmaceuticals by Impregnation onto Porous Carriers

AU - Muzzio, Fernando

AU - Glasser, Benjamin

AU - Grigorov, Plamen

PY - 2018/8

Y1 - 2018/8

N2 - Figure 1. SEM Pictures of pure Neusilin ® and impregnated with Fenofibrate at 30% loading. Invention Summary: Rutgers scientists have developed a novel platform of pharmaceutical product development by utilizing fluid bed impregnation (FBI) of API solutions onto porous carriers. Impregnation of solutions into porous carriers allows extremely uniform distribution of small amounts of material, which can be used for drug dosage regulation. Currently, the method can be adjusted for drug content as low as 0.1% and as high as 10%, thus spanning the entire range of interest for poorly soluble, highly potent compounds in oral delivery applications. The drug release profile can also be controlled through the manufacturing process. Since the impregnated material can be filled directly into capsules, many inactive substances that were previously required for formula stability throughout encapsulation (i.e. compression aids, glidants, surfactants, disintegrants, or lubricants) can be eliminated as well. Also, the FBI method is uniquely suited for drug formulation development and clinical supply manufacturing, as it is safer than processes that require drugs to be handled in dry, powder form. Market Application: Therapeutics Clinical Supply Manufacturing Product Formulation and Development Drug Loading Drug Delivery Controlled Release Porous Carrier Technology Advantages: Approach eliminates all API operations after synthesis and purification (i.e., crystallization, drying, milling) making issues related to API crystallinity, physical stability, flow, cohesion, electrostatics, and particle size distribution no longer relevant Extremely uniform material content in finished dosages Enhances deliverability of poorly soluble drugs Significant simplification of product manufacturing sequence Safety and environmental improvements Simplified scale-up procedure Reduced number of critical raw material attributes and control parameters Intellectual Property & Development Status: US patent application allowed, European patent application pending, available for licensing and/or research collaboration.

AB - Figure 1. SEM Pictures of pure Neusilin ® and impregnated with Fenofibrate at 30% loading. Invention Summary: Rutgers scientists have developed a novel platform of pharmaceutical product development by utilizing fluid bed impregnation (FBI) of API solutions onto porous carriers. Impregnation of solutions into porous carriers allows extremely uniform distribution of small amounts of material, which can be used for drug dosage regulation. Currently, the method can be adjusted for drug content as low as 0.1% and as high as 10%, thus spanning the entire range of interest for poorly soluble, highly potent compounds in oral delivery applications. The drug release profile can also be controlled through the manufacturing process. Since the impregnated material can be filled directly into capsules, many inactive substances that were previously required for formula stability throughout encapsulation (i.e. compression aids, glidants, surfactants, disintegrants, or lubricants) can be eliminated as well. Also, the FBI method is uniquely suited for drug formulation development and clinical supply manufacturing, as it is safer than processes that require drugs to be handled in dry, powder form. Market Application: Therapeutics Clinical Supply Manufacturing Product Formulation and Development Drug Loading Drug Delivery Controlled Release Porous Carrier Technology Advantages: Approach eliminates all API operations after synthesis and purification (i.e., crystallization, drying, milling) making issues related to API crystallinity, physical stability, flow, cohesion, electrostatics, and particle size distribution no longer relevant Extremely uniform material content in finished dosages Enhances deliverability of poorly soluble drugs Significant simplification of product manufacturing sequence Safety and environmental improvements Simplified scale-up procedure Reduced number of critical raw material attributes and control parameters Intellectual Property & Development Status: US patent application allowed, European patent application pending, available for licensing and/or research collaboration.

KW - Drug Delivery

KW - Drug Delivery Methods.

KW - therapeutic

UR - http://rutgers.technologypublisher.com/tech/Formulation_and_Manufacture_of_Pharmaceuticals_by_Impregnation_onto_Porous_Carriers

M3 - Innovation

ER -